Exploring the Clinical Benefits of Antiviral Therapy in Decreasing Complications Associated with the Influenza Virus


Data have shown that the use of antiviral treatment in the early stages of influenza can decrease the duration of fever and illness symptoms and can even lessen the risk of complications associated with influenza. New drug approvals create opportunities to effectively and safely treat influenza. Pharmacists should identify patients who may have influenza or who are at a high risk and be able to manage these patients’ influenza to diminish associated complications, hospitalizations, and mortality rates.

Speakers: James Lewis, PharmD, FIDSA, Oregon Health and Science University; Carrie Koenigsfeld, PharmD, Drake University

Register today at https://www.pharmacytimes.org/go/influenza2019.


Pharmacist Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Explore the etiology, pathophysiology and patient populations at high risk for influenza related complications.
  2. Explain the mechanisms of action and adverse effect profiles of available and recently approved antivirals for the treatment of the influenza virus.
  3. Identify the role of the community pharmacist in educating patients about the available and recently approved antivirals for treatment of the influenza virus.


Presented by Pharmacy Times Continuing Education and supported by an independent educational grant from Genentech, Inc.

Learning Level: Level 2
Track: Satellite Symposia
Session Time Slot(s): 
Sunday, March 24
6:00 AM - 8:00 AM
Grand Hyatt Seattle - Leonesa II, III
ACPE Pharmacist: 0290-0000-19-013-L01-P
CEUs Pharmacist: 0.15
Activity Type: